市場調查報告書

頭孢菌素的全球市場:產業分析,市場佔有率、規模、成長率、機會、未來預測

Cephalosporin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

出版商 IMARC Services Private Limited 商品編碼 865010
出版日期 內容資訊 英文 103 Pages
商品交期: 2-3個工作天內
價格
頭孢菌素的全球市場:產業分析,市場佔有率、規模、成長率、機會、未來預測 Cephalosporin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024
出版日期: 2019年06月10日內容資訊: 英文 103 Pages
簡介

本報告提供全球頭孢菌素的市場相關分析,市場整體結構,市場規模的變化、預測 (過去、今後6年份),各世代、各給藥途徑、各用途及各地區詳細趨勢,價值鏈結構與趨勢,主要的推動及阻礙市場要素,市場競爭環境,主要企業的簡介等相關調查。

第1章 序論

第2章 分析範圍、手法

第3章 摘要整理

第4章 簡介

  • 概要
  • 產業的主要趨勢

第5章 全球頭孢菌素市場

  • 市場概要
  • 市場規模的成果值
  • 市場區隔:各世代
  • 市場區隔:各給藥途徑 (RoA)
  • 市場區隔:各用途
  • 市場區隔:各地區
  • 市場規模的預測值

第6章 各世代的市場區隔

  • 第一世代
    • 市場趨勢
    • 市場預測
  • 第二世代
  • 第三代
  • 第四代
  • 第五代

第7章 各給藥途徑的市場區隔

  • 注射
  • 口服給藥

第8章 各用途的市場區隔

  • 呼吸道感染疾病
  • 皮膚感染疾病
  • 耳朵感染疾病
  • 泌尿道感染
  • 性感染疾病
  • 其他

第9章 各地區的市場區隔

  • 亞太地區市場
  • 歐洲市場
  • 北美市場
  • 中東、非洲市場
  • 南美市場

第10章 SWOT分析

  • 概要
  • 優勢、弱點、機會、威脅

第11章 價值鏈分析

第12章 波特的五力分析

  • 概要
  • 買主談判力
  • 供應商談判力
  • 企業間競爭的激烈程度
  • 新加入企業的威脅
  • 替代產品的威脅

第13章 價格分析

  • 價格指數
  • 價格結構
  • 毛利率分析

第14章 競爭環境

  • 市場結構
  • 主要企業
  • 主要企業的簡介
    • Allergan Plc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Lupin Limited (Lupin Pharmaceuticals, Inc.)
    • Merck & Co. Inc.
    • Novartis International AG (Sandoz)
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Abbott
    • Ranbaxy
    • Merck
目錄
Product Code: SR1019C75_Report

The global cephalosporin market size was worth US$ 11.4 Billion in 2018. Cephalosporins are beta-lactam antibiotics that function in the way similar to penicillin. These broad-spectrum drugs help in treating numerous bacterial infections such as pneumonia, kidney infections, bone infections, meningitis and various sexually transmitted diseases (STDs). There are currently five generations of cephalosporin drugs available in the market with a slight difference in their antibacterial spectrum. These medicines are also differentiated on the basis their administration, excretion, absorption and the duration of the effect of cephalosporin on the body. There are two ways to administer cephalosporin drugs, namely, oral and intravenous (IV). A course of oral cephalosporins is generally used for curing minor infections that are easy to treat such as strep throat. Whereas, IVs are utilized for more severe infections, like meningitis, as these medicines reach tissues quickly than those administered orally.

At present, the rapidly increasing water and air pollution are the primary reasons for the prevalence of infectious diseases across the globe. This has provided a boost to the demand for cephalosporin drugs worldwide. Other than this, various organizations around the world are taking initiatives to improve the development and delivery of antibiotic treatments. One such program is the Global Antibiotic Research and Development Partnership (GARDP), which is a not-for-profit R&D organization formed by the Drugs for Neglected Disease initiative (DNDi) and World Health Organization (WHO). It focusses on the promotion of public-private partnerships for increasing R&D of new antimicrobial diagnostics and agents. The formation of these partnerships is expected to play a significant role in the growth of the cephalosporin market. Looking forward, IMARC Group expects the market to reach a value of US$ 13.3 Billion by 2024, registering a CAGR of around 3% during 2019-2024.

Report Coverage:

  • Historical, Current and Future Market Trends

Market Breakup by Generation:

  • First Generation
  • Second Generation
  • Third Generation
  • Fourth Generation
  • Fifth Generation

Market Breakup by Route of Administration:

  • Injection
  • Oral

Market Breakup by Application:

  • Respiratory Tract
  • Skin Infection
  • Ear Infection
  • Urinary Tract Infection
  • Sexually Transmitted Infection
  • Others

Market Breakup by Region:

  • Asia Pacific
  • Europe
  • North America
  • Middle East and Africa
  • Latin America

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Limited (Lupin Pharmaceuticals, Inc., Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Abbott, Ranbaxy, Merck, etc.

Key Questions Answered in This Report:

  • How has the global cephalosporin market performed so far and how will it perform in the coming years?
  • What are the key regional markets in the global cephalosporin industry?
  • What is the breakup of the market based on the generation?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the global cephalosporin industry?
  • What are the key driving factors and challenges in the global cephalosporin industry?
  • What is the structure of the global cephalosporin industry and who are the key players?
  • What is the degree of competition in the global cephalosporin industry?
  • What are the profit margins in the global cephalosporin industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cephalosporin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Market Breakup by Generation
  • 5.4 Market Breakup by Route of Administration
  • 5.5 Market Breakup by Application
  • 5.6 Market Breakup by Region
  • 5.7 Market Forecast

6 Market Breakup by Generation

  • 6.1 First Generation
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Second Generation
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Third Generation
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Fourth Generation
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Fifth Generation
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Injection
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Oral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Respiratory Tract
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Skin Infection
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ear Infection
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Urinary Tract Infection
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Sexually Transmitted Infection
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Region

  • 9.1 Asia Pacific
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Europe
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 North America
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Middle East and Africa
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Latin America
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

  • 13.1 Price Indicators
  • 13.2 Price Structure
  • 13.3 Margin Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Allergan Plc.
    • 14.3.2 Bristol-Myers Squibb Company
    • 14.3.3 F. Hoffmann-La Roche Ltd.
    • 14.3.4 GlaxoSmithKline plc
    • 14.3.5 Lupin Limited (Lupin Pharmaceuticals, Inc.
    • 14.3.6 Merck & Co. Inc.
    • 14.3.7 Novartis International AG (Sandoz)
    • 14.3.8 Pfizer Inc.
    • 14.3.9 Teva Pharmaceutical Industries Ltd.
    • 14.3.10 Abbott
    • 14.3.11 Ranbaxy
    • 14.3.12 Merck

List of Figures

  • Figure 1: Global: Cephalosporin Market: Major Drivers and Challenges
  • Figure 2: Global: Cephalosporin Market: Sales Value (in Billion US$), 2013-2018
  • Figure 3: Global: Cephalosporin Market: Breakup by Generation (in %), 2018
  • Figure 4: Global: Cephalosporin Market: Breakup by Route of Administration (in %), 2018
  • Figure 5: Global: Cephalosporin Market: Breakup by Application (in %), 2018
  • Figure 6: Global: Cephalosporin Market: Breakup by Region (in %), 2018
  • Figure 7: Global: Cephalosporin Market Forecast: Sales Value (in Billion US$), 2019-2024
  • Figure 8: Global: Cephalosporin (First Generation) Market: Sales Value (in Million US$), 2013-2018
  • Figure 9: Global: Cephalosporin (First Generation) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 10: Global: Cephalosporin (Second Generation) Market: Sales Value (in Million US$), 2013-2018
  • Figure 11: Global: Cephalosporin (Second Generation) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 12: Global: Cephalosporin (Third Generation) Market: Sales Value (in Million US$), 2013-2018
  • Figure 13: Global: Cephalosporin (Third Generation) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 14: Global: Cephalosporin (Fourth Generation) Market: Sales Value (in Million US$), 2013-2018
  • Figure 15: Global: Cephalosporin (Fourth Generation) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 16: Global: Cephalosporin (Fifth Generation) Market: Sales Value (in Million US$), 2013-2018
  • Figure 17: Global: Cephalosporin (Fifth Generation) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 18: Global: Cephalosporin (Injection) Market: Sales Value (in Million US$), 2013-2018
  • Figure 19: Global: Cephalosporin (Injection) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 20: Global: Cephalosporin (Oral) Market: Sales Value (in Million US$), 2013-2018
  • Figure 21: Global: Cephalosporin (Oral) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 22: Global: Cephalosporin (Respiratory Tract) Market: Sales Value (in Million US$), 2013-2018
  • Figure 23: Global: Cephalosporin (Respiratory Tract) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 24: Global: Cephalosporin (Skin Infection) Market: Sales Value (in Million US$), 2013-2018
  • Figure 25: Global: Cephalosporin (Skin Infection) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 26: Global: Cephalosporin (Ear Infection) Market: Sales Value (in Million US$), 2013-2018
  • Figure 27: Global: Cephalosporin (Ear Infection) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 28: Global: Cephalosporin (Urinary Tract Infection) Market: Sales Value (in Million US$), 2013-2018
  • Figure 29: Global: Cephalosporin (Urinary Tract Infection) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 30: Global: Cephalosporin (Sexually Transmitted Infection) Market: Sales Value (in Million US$), 2013-2018
  • Figure 31: Global: Cephalosporin (Sexually Transmitted Infection) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 32: Global: Cephalosporin (Other Applications) Market: Sales Value (in Million US$), 2013-2018
  • Figure 33: Global: Cephalosporin (Other Applications) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 34: Asia Pacific: Cephalosporin Market: Sales Value (in Million US$), 2013-2018
  • Figure 35: Asia Pacific: Cephalosporin Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 36: Europe: Cephalosporin Market: Sales Value (in Million US$), 2013-2018
  • Figure 37: Europe: Cephalosporin Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 38: North America: Cephalosporin Market: Sales Value (in Million US$), 2013-2018
  • Figure 39: North America: Cephalosporin Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 40: Middle East and Africa: Cephalosporin Market: Sales Value (in Million US$), 2013-2018
  • Figure 41: Middle East and Africa: Cephalosporin Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 42: Latin America: Cephalosporin Market: Sales Value (in Million US$), 2013-2018
  • Figure 43: Latin America: Cephalosporin Market Forecast: Sales Value (in Million US$), 2019-2024

List of Tables

  • Table 1: Global: Cephalosporin Market: Key Industry Highlights, 2018 and 2024
  • Table 2: Global: Cephalosporin Market Forecast: Breakup by Generation (in Million US$), 2019-2024
  • Table 3: Global: Cephalosporin Market Forecast: Breakup by Route of Administration (in Million US$), 2019-2024
  • Table 4: Global: Cephalosporin Market Forecast: Breakup by Application (in Million US$), 2019-2024
  • Table 5: Global: Cephalosporin Market Forecast: Breakup by Region (in Million US$), 2019-2024
  • Table 6: Global: Cephalosporin Market Structure
  • Table 7: Global: Cephalosporin Market: Key Players